NASDAQ:IBIO iBio Q4 2026 Earnings Results & Report $0.87 -0.05 (-5.33%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.88 +0.01 (+1.26%) As of 10/9/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. iBio beat analyst earnings expectations in its Q4 2026 results, released August 28, 2026. The company reported EPS of -$0.04 versus the -$0.0655 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2026Report DateAugust 28, 2026TimeBefore Market OpensConference Call7:00 AM ET iBio EPS ResultsActual EPS-$0.04Consensus EPS -$0.0655Beat/MissBeat by +$0.0255One Year Ago EPSN/AEPS Beat Rate1 of last 5 quartersiBio Revenue ResultsActual RevenueN/AExpected Revenue$0.08 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsiBio's Q1 2027 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) iBio Q4 2026 Earnings FAQ Did iBio beat earnings estimates for Q4 2026? iBio (NASDAQ:IBIO) reported earnings of -$0.04 per share for Q4 2026, beating the consensus estimate of -$0.0655. The report was announced on Friday, August 28, 2026. When is iBio's next earnings date? iBio's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for iBio on the company's earnings history page. iBio Earnings HeadlinesiBio (NASDAQ:IBIO) and Organogenesis (NASDAQ:ORGO) Head to Head ReviewOctober 1, 2026 | americanbankingnews.comHC Wainwright & Co. initiates coverage of iBio with a buy ratingSeptember 17, 2026 | msn.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 11 at 1:00 AM | Base Camp Trading (Ad)iBio to Participate in the 2026 Wells Fargo Annual Healthcare ConferenceSeptember 1, 2026 | globenewswire.comIBio Reports Wider FY '26 Loss As IBIO-600 Phase 1 For Obesity ProgressesAugust 29, 2026 | rttnews.comiBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateAugust 28, 2026 | finanznachrichten.deSee More iBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email. Email Address About iBioiBio (NASDAQ:IBIO) is a biotechnology company focused on the discovery and development of next-generation biotherapeutics. The company uses artificial intelligence, machine learning and computational biology to identify promising antibody candidates, characterize their target epitopes and support the design of potentially differentiated medicines. iBio’s technology platform is designed to help address challenges in antibody discovery and development, including selecting suitable biological targets and engineering antibodies with desired characteristics. The company has pursued a pipeline of wholly owned and partnered programs in areas such as oncology, autoimmune disease and other conditions with significant unmet medical needs. Founded in 2008 and headquartered in Bryan, Texas, iBio previously operated as a biologics manufacturing and development company before shifting its strategic emphasis toward AI-enabled drug discovery. The company’s current activities are primarily research and development oriented, with commercial opportunities expected to depend on advancing its pipeline and forming strategic collaborations.View iBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
